CytomX Therapeutics, Inc. (CTMX) Operating cash flow 2016–2025
CytomX Therapeutics, Inc. (CTMX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$75.6MFY2025 · since FY2016: -$2.0M → -$75.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$75.6M | +12.3% |
| FY2024 | -$86.2M | -53.9% |
| FY2023 | -$56.0M | +49.4% |
| FY2022 | -$110.8M | +6.9% |
| FY2021 | -$119.0M | -2363.4% |
| FY2020 | $5.3M | +103.7% |
| FY2019 | -$140.5M | -86.0% |
| FY2018 | -$75.5M | -144.3% |
| FY2017 | $170.4M | +8484.5% |
| FY2016 | -$2.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CTMX financial trends
CTMX RevenueCTMX Net incomeCTMX Net marginCTMX Gross profitCTMX Gross marginCTMX Operating incomeCTMX Operating marginCTMX Free cash flowCTMX Capital expendituresCTMX Return on equityCTMX Stock buybacksCTMX Dividends paidCTMX Total assetsCTMX Total liabilitiesCTMX Shareholders’ equityCTMX overview →